These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25659907)

  • 1. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
    Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
    J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.
    Gårdsvoll H; Jacobsen B; Kriegbaum MC; Behrendt N; Engelholm L; Østergaard S; Ploug M
    J Biol Chem; 2011 Sep; 286(38):33544-56. PubMed ID: 21799009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.
    Gårdsvoll H; Kjaergaard M; Jacobsen B; Kriegbaum MC; Huang M; Ploug M
    J Biol Chem; 2011 Dec; 286(50):43515-26. PubMed ID: 22025616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
    Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
    Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
    Gårdsvoll H; Ploug M
    J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and ligand interactions of the urokinase receptor (uPAR).
    Kjaergaard M; Hansen LV; Jacobsen B; Gardsvoll H; Ploug M
    Front Biosci; 2008 May; 13():5441-61. PubMed ID: 18508598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
    Liang OD; Chavakis T; Kanse SM; Preissner KT
    J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of the interaction between vitronectin and the urokinase receptor.
    Okumura Y; Kamikubo Y; Curriden SA; Wang J; Kiwada T; Futaki S; Kitagawa K; Loskutoff DJ
    J Biol Chem; 2002 Mar; 277(11):9395-404. PubMed ID: 11773078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
    Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
    Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
    Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
    Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
    Li Y; Lawrence DA; Zhang L
    J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography.
    Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
    Data Brief; 2015 Dec; 5():107-13. PubMed ID: 26504891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of the urokinase receptor in a ligand-free form.
    Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
    J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.
    Sidenius N; Andolfo A; Fesce R; Blasi F
    J Biol Chem; 2002 Aug; 277(31):27982-90. PubMed ID: 12034711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
    J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
    Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
    Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.